Article Details
Retrieved on: 2018-05-08 18:30:00
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
<div><b>Benchmark Capital</b> Advisors boosted its stake in shares of Galectin Therapeutics by 19.7% during the 1st quarter. <b>Benchmark Capital</b> Advisors now owns 221,700 shares of the company's stock worth $1,051,000 after acquiring an additional 36,500 shares in the last quarter. Finally, Wedbush Securities ...</div>
Article found on:
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here